Joint Venture18 Dec 2025, 03:52 pm
Lupin Signs Exclusive Licensing Agreement with Neopharmed for Gastroenterology Brand Plasil in the Philippines and Brazil
AI Summary
Global pharma major Lupin Limited has signed an exclusive licensing agreement with Neopharmed Gentili S.p.A for marketing and promotional rights for the Gastroenterology brand, Plasil® (metoclopramide), in the Philippines and Brazil. This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets. Neopharmed will oversee product supply in the Philippines, while in Brazil, production will be shifted to Medquimica’s manufacturing facility. Plasil® is widely acknowledged for its efficacy in treating nausea, vomiting, and motility disorders.
Key Highlights
- Lupin's subsidiaries in the Philippines and Brazil have signed an exclusive licensing agreement with Neopharmed Gentili S.p.A for marketing and promotional rights for Plasil®
- This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
- Neopharmed will oversee product supply in the Philippines, ensuring quality and compliance with global standards
- In Brazil, production will be shifted to Medquimica’s manufacturing facility
- Plasil® is widely acknowledged for its efficacy in treating nausea, vomiting, and motility disorders